Tobias Pukrop

Prof. Dr. Tobias Pukrop

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
LSLaila Siam
Laila Siam
ABAnnalen Bleckmann
Annalen Bleckmann
HCHan-Ning Chaung
Han-Ning Chaung
AMAlexander Mohr
Alexander Mohr
FKFlorian Klemm
Florian Klemm
TPTobias Pukrop
Tobias Pukrop
The metastatic infiltration at the metastasis/brain parenchyma-interface is very heterogeneous and has a significant impact on survival in a prospective study

25 October 2018 in Glia
Verified
Journal Article
Closed access
PDF file
RBRaquel Blazquez
Raquel Blazquez
DWDarius Wlochowitz
Darius Wlochowitz
AWAlexander Wolff
Alexander Wolff
SSStefanie Seitz
Stefanie Seitz
AWAstrid Wachter
Astrid Wachter
TPTobias Pukrop
Tobias Pukrop

31 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MPMartin Proescholdt
Martin Proescholdt
PSPetra Schödel
Petra Schödel
CDChristian Doenitz
Christian Doenitz
TPTobias Pukrop
Tobias Pukrop
Julius HöhneJulius Höhne
Julius Höhne
KSKarl-Michael Schebesch
Karl-Michael Schebesch
The multidisciplinary management of patients with brain metastases (BM) consists of surgical resection, different radiation treatment modalities, cytotoxic chemotherapy, and targeted molecular treatment. This review presents the current state of neurosurgical technology applied to achieve maximal resection with minimal morbidity as a treatment paradigm in patients with BM. In addition, we discuss the contribution of neurosurgical resection on functional outcome, advanced systemic treatment strategies, and enhanced understanding of the tumor biology.

26 June 2017 in Frontiers in Oncology
Verified
Journal Article
Open access
MBMichaela Bayerlová
Michaela Bayerlová
KMKerstin Menck
Kerstin Menck
FKFlorian Klemm
Florian Klemm
AWAlexander Wolff
Alexander Wolff
TPTobias Pukrop
Tobias Pukrop
ABAnnalen Bleckmann
Annalen Bleckmann
Breast cancer is a heterogeneous disease and has been classified into five molecular subtypes based on gene expression profiles. Signaling processes linked to different breast cancer molecular subtypes and different clinical outcomes are still poorly understood. Aberrant regulation of Wnt signaling has been implicated in breast cancer progression. In particular Ror1/2 receptors and several other members of the non-canonical Wnt signaling pathway were associated with aggressive breast cancer behavior. However, Wnt signals are mediated via multiple complex pathways and it is clinically important to determine which particular Wnt cascades, including their domains and targets, are deregulated in poor prognosis breast cancer. To investigate activation and outcome of the Ror2-dependent non-canonical Wnt signaling pathway we overexpressed the Ror2 receptor in MCF-7 and MDA-MB231 breast cancer cells, stimulated the cells with its ligand Wnt5a, and we knocked-down Ror1 in MDA-MB231 cells. We measured the invasive capacity of perturbed cells to assess phenotypic changes and mRNA was profiled to quantify gene expression changes. Differentially expressed genes were integrated into a literature-based non-canonical Wnt signaling network. The results were further used in the analysis of an independent dataset of breast cancer patients with metastasis-free survival annotation. Overexpression of the Ror2 receptor, stimulation with Wnt5a as well as the combination of both perturbations enhanced invasiveness of MCF-7 cells. The expression-responsive targets of Ror2 overexpression in MCF-7 induced a Ror2/Wnt module of the non-canonical Wnt signaling pathway. These targets alter regulation of other pathways involved in cell remodeling processing and cell metabolism. Furthermore, the genes of the Ror2/Wnt module were assessed as a gene signature in patient gene expression data and showed an association with clinical outcome. In summary, results of this study indicate a role of a newly defined Ror2/Wnt module in breast cancer progression and present a link between Ror2 expression and increased cell invasiveness.

Verified
Journal Article
Open access
PDF file
DHDaniel Heudobler
Daniel Heudobler
MRMichael Rechenmacher
Michael Rechenmacher
FLFlorian Lüke
Florian Lüke
MVMartin Vogelhuber
Martin Vogelhuber
TPTobias Pukrop
Tobias Pukrop
ARAlbrecht Reichle
Albrecht Reichle
In most clinical trials, thiazolidinediones do not show any relevant anti-cancer activity when used as mono-therapy. Clinical inefficacy contrasts ambiguous pre-clinical data either favoring anti-tumor activity or tumor promotion. However, if thiazolidinediones are combined with additional regulatory active drugs, so-called ‘master modulators’ of tumors, i.e., transcriptional modulators, metronomic low-dose chemotherapy, epigenetically modifying agents, protein binding pro-anakoinotic drugs, such as COX-2 inhibitors, IMiDs, etc., the results indicate clinically relevant communicative reprogramming of tumor tissues, i.e., anakoinosis, meaning ‘communication’ in ancient Greek. The concerted activity of master modulators may multifaceted diversify palliative care or even induce continuous complete remission in refractory metastatic tumor disease and hematologic neoplasia by establishing novel communicative behavior of tumor tissue, the hosting organ, and organism. Re-modulation of gene expression, for example, the up-regulation of tumor suppressor genes, may recover differentiation, apoptosis competence, and leads to cancer control—in contrast to an immediate, ‘poisoning’ with maximal tolerable doses of targeted/cytotoxic therapies. The key for uncovering the therapeutic potential of Peroxisome proliferator-activated receptor γ (PPARγ) agonists is selecting the appropriate combination of master modulators for inducing anakoinosis: Now, anakoinosis is trend setting by establishing a novel therapeutic pillar while overcoming classic obstacles of targeted therapies, such as therapy resistance and (molecular-)genetic tumor heterogeneity.

6 March 2025 in Molecular and Cellular Endocrinology
Verified
Journal Article
Open access
CBChristina Brummer
Christina Brummer
KSKatrin Singer
Katrin Singer
KRKathrin Renner
Kathrin Renner
CBChristina Bruss
Christina Bruss
CHClaus Hellerbrand
Claus Hellerbrand
MKMarina Kreutz
Marina Kreutz
Obesity promotes adipose tissue inflammation and leads to impaired local but also systemic immune cell homeostasis. This chronic low-grade inflammation plays a significant role in the development of obesity-associated secondary diseases such as metabolic associated fatty liver disease or cancer. The spleen as the central organ of immune cell regulation is anatomically directly connected to the visceral adipose tissue and the liver via the portal vein circulation. However, the inter-organ crosstalk and linkage between obesity-induced systemic, hepatic and splenic immune cell dysregulation is not clearly outlined. In this study blood, spleen, and liver immune cells of non-obese wildtype vs. leptin deficient obese BTBR mice were isolated and analyzed in terms of leukocyte composition by flow cytometry. Significant differences between circulating, spleen- and liver-resident immune cell distribution revealed, that obesity-induced hepatic and systemic immune cell dysregulation is distinct from splenic immune cell reprogramming. Fatty liver inflammation was associated with splenic myeloid derived suppressor cell (MDSC) and natural killer T cell (NKT) enrichment whereas loss of hepatic T and B cells was not reflected by the splenic lymphocyte landscape. Correlation analysis confirmed a selective strong positive correlation between spleen and liver MDSC and NKT cell distribution indicating that the spleen-liver axis modulates obesity-induced immune dysregulation in a cell-specific manner. Similar results were observed in a diet-induced obesity mouse model. These data provide novel insights into the role of the spleen-liver axis in obesity-induced inflammation and foster the understanding of obesity-associated complications such as fatty liver disease and cancer.